Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold
Sana Biotechnology Inc SANA
$3.13
▼ -3.69%
($-0.12)
⬇️ Below Yest. Low
🔥 High Short Interest
🎢 High Beta
🗓️ Earnings Next Week
Open
$3.25
Prev Close
$3.25
Day Range
$3.09 – $3.32
52W Range
$2.61 – $6.55
Market Cap
$871.05M
Beta
2.12
EPS (TTM)
$-0.94
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-04 |
| Shares Out. | 278,290,000 |
| Website | sana.com/ ↗ |
| Phone | 12067017914 |
| Employees | 142 |
| Net Income | -$47.2M |
| Free Cash Flow | -$133.6M |
| Total Assets | $373.6M |
| Total Liabilities | $254.4M |
| Equity | $119.2M |
About Sana Biotechnology Inc
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Sana Biotechnology Inc is a publicly traded company under the ticker symbol SANA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)